What is the clinical evidence from this study?

Study design: Review. Population: Acute Ischemic Stroke with Atrial Fibrillation (n=5441). Intervention: Early NOAC initiation (≤4 days) vs. Late NOAC initiation (≥5 days). Primary outcome: Composite of recurrent ischemic stroke, symptomatic ICH, or unclassified stroke at 30 days (OR 0.70, 95% CI 0.50-0.98).

What does this research mean for the field?

Early initiation of non-vitamin K oral anticoagulants within 4 days of acute ischemic stroke reduces the 30-day composite risk of recurrent ischemic stroke, symptomatic intracranial hemorrhage, or unclassified stroke compared to late initiation. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research examines the safety and effectiveness of early anticoagulation in patients with atrial fibrillation experiencing acute ischemic stroke.

April 25, 2026Journal of Stroke0 citationsOpen Access

Early Anticoagulation in Acute Ischemic Stroke With Atrial Fibrillation

HPH Park MKMasatoshi Koga KHKeun-Sik Hong

Key Result

Early NOAC initiation within 4 days of acute ischemic stroke reduced the 30-day composite of recurrent ischemic stroke, symptomatic ICH, or unclassified stroke compared to late initiation (OR 0.70).

Key Points

This research examines the safety and effectiveness of early anticoagulation in patients with atrial fibrillation experiencing acute ischemic stroke.
Conducted a randomized controlled trial comparing early initiation of non-vitamin K oral anticoagulants to traditional methods.
Included patients diagnosed with acute ischemic stroke and atrial fibrillation, analyzing outcomes related to stroke recurrence and hemorrhage.
Utilized an individual patient data meta-analysis for comprehensive assessment.
Early anticoagulation significantly reduced risk of recurrent ischemic events compared to no early treatment (specific rates not detailed).
No significant increase in intracranial hemorrhage rates was found among treated individuals (specific data not provided).
Findings highlight the need for careful consideration of anticoagulation strategies in diverse patient populations.

Structured PICO

Does early initiation of non-vitamin K oral anticoagulants prevent recurrent ischemic stroke without increasing intracranial hemorrhage in patients with atrial fibrillation and acute ischemic stroke?

Population

Patients with atrial fibrillation who experience acute ischemic stroke (AIS)

Intervention

Early initiation of non-vitamin K oral anticoagulants (NOACs)

Comparator

Late or delayed initiation of non-vitamin K oral anticoagulants (NOACs), or vitamin K antagonists

This narrative review synthesizes recent trial data supporting the safety and efficacy of early NOAC initiation over delayed initiation in patients with AF-related acute ischemic stroke.

Main Result

Effect estimate: OR 0.70 (95% CI 0.50-0.98)

Absolute Event Rate: 2.12% vs 3.02%

Limitations

Insufficient data on the safety and efficacy of early NOAC initiation in patients with very severe stroke (NIHSS >15).
Uncertain safety and efficacy in patients with hemorrhagic transformation.
Underrepresentation of Asian populations in clinical trials, who may have a higher risk of bleeding.

Abstract

Patients with atrial fibrillation who experience acute ischemic stroke (AIS) are at high risk of early recurrent ischemic stroke or systemic embolism. Timely initiation of anticoagulation is essential to prevent subsequent ischemic events but must be carefully balanced against the risk of hemorrhagic transformation or intracranial hemorrhage. Historically, early anticoagulation therapy with heparin or vitamin K antagonists for AIS has shown uncertain benefits. The safety and efficacy of early initiation of non-vitamin K oral anticoagulants, initially suggested by observational studies, have been confirmed by randomized controlled trials and further supported by an individual patient data meta-analysis. However, uncertainties remain in specific populations, including those with severe stroke, hemorrhagic transformation, and Asian patients, who are at an increased risk of intracranial bleeding and are underrepresented in clinical trials.

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Park et al. (Thu,) conducted a review in Acute Ischemic Stroke with Atrial Fibrillation (n=5,441). Early NOAC initiation (≤4 days) vs. Late NOAC initiation (≥5 days) was evaluated on Composite of recurrent ischemic stroke, symptomatic ICH, or unclassified stroke at 30 days (OR 0.70, 95% CI 0.50-0.98). Early NOAC initiation within 4 days of acute ischemic stroke reduced the 30-day composite of recurrent ischemic stroke, symptomatic ICH, or unclassified stroke compared to late initiation (OR 0.70).

synapsesocial.com/papers/69ec59c688ba6daa22dab830 https://doi.org/https://doi.org/10.5853/jos.2025.05211

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Perguntar à IA

Bookmark

View Full Paper